Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus
New York, NY– June 27, 2019. The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […] Read More